Olivier Danos

Company: REGENXBIO

Job title: Chief Scientific Officer

Seminars:

Case Study: Revolutionizing Retinal Disease Treatment with Gene Therapy: An Insight into Regenxbio’s Retinal Pipeline 2:30 pm

• Utilizing its proprietary NAV AAV platform to develop therapies targeting rare and prevalent retinal diseases, offering potential long-term, one-time treatments • Key candidates include RGX-314, aimed at treating wet AMD and diabetic retinopathy, designed to reduce the need for frequent anti-VEGF injections, showing promising clinical data • Regenxbio’s retinal pipeline targets not only large…Read more

day: Day 1- Clinical 2